USPTO serial 79411970
DISCO PHARMACEUTICALS
Reviewed by CopyMark Law Group
Status 654
- Filing date
- Status date
- Registration date
- —
- Examiner
- RUIZ SANTIAGO, REBECCA E
- Law office
- TMO LAW OFFICE 130
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with DISCO PHARMACEUTICALS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christopher M. Kindel
Christopher M. Kindel Pirkey Barber PLLC1801 East 6th Street, Suite 300Austin, TX 78702United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Active chemical ingredients for use in the manufacture of pharmaceuticals for treating neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; biomolecules, in particular biological macromolecules, namely, proteins for use in the manufacture of pharmaceuticals; all the foregoing for scientific and industrial purposes for the human pharmaceutical industry and excluding products for biomedical research and testing. | ACTIVE | — |
| 005 | Chemical preparations for medical use, namely, for treating neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; pharmaceutical preparations for the prevention and treatment of neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; immunostimulatory compositions being pharmaceutical preparations for the prevention and treatment of neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; vaccines; adjuvant immunostimulants, namely, adjuvants for medical purposes; pharmaceuticals and medicines based on biological micromolecules for treating neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; pharmaceuticals and medicines, namely, enzymes and proteins for medical use in protein and enzyme replacement therapy; Pharmaceutical preparations for gene therapy for the treatment of neurological, neuromuscular, neurodegenerative, cardiovascular diseases, infectious diseases, allergies, autoimmune disorders, tumours, metabolic disorders, and inherited genetic diseases; all of the foregoing excluding nutritional supplements, phytotherapy preparations for medical purposes, and products for biomedical research and testing | ACTIVE | — |
| 042 | Scientific and technological services and research services, in particular for identifying and characterizing biological macromolecules, namely, biological and chemical research and analysis; development of pharmaceuticals preparations or vaccines; conducting of and scientific support for preclinical or clinical studies, namely, scientific research in the nature of conducting pre-clinical and clinical trials for others; all of the foregoing excluding products for biomedical research and testing | ACTIVE | — |
| 044 | Medical services, in particular for therapeutic and preventative treatment of tumours, infectious diseases, autoimmune disorders and allergies, for treating inherited genetic diseases and for protein and enzyme replacement therapy, and for treating neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for treating metabolic disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 4, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jun 4, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| May 18, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 18, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| May 7, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Nov 3, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 3, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 3, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Aug 5, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 5, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 5, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 27, 2025 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Jun 25, 2025 | CREV | CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED | — |
| Feb 22, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 5, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 5, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 31, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 30, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 21, 2024 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Dec 18, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 13, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 13, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 12, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |